Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus. Trial part 1 is a five-period cross-over trial with incomplete block-design in subjects with type 1 diabetes where each subject will be randomised to five out of the ten possible treatments. Each treatment consists of an injection of the insulin product followed by a euglycemic clamp with a washout period of 7-15 days between treatments. Trial part 2 is a three-period cross-over trial with complete blockdesign in subjects with type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a euglycaemic clamp with a washout period of 7-15 days between treatments.
Interventions
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
Single dose administrated subcutaneously (s.c., under the skin).
DRUGinsulin degludec
Single dose administrated subcutaneously (s.c., under the skin).
DRUGinsulin aspart
Single dose administrated subcutaneously (s.c., under the skin).
DRUGbiphasic insulin aspart 30
Single dose administrated subcutaneously (s.c., under the skin) as comparator.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 69 Years
Healthy volunteers
Yes
Inclusion criteria
* The subject will be a male volunteer, who is considered to be generally healthy, except for underlying diabetes mellitus and concomitant medical complications (e.g. hypertension) based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator * Glycosylated haemoglobin A1c (HbA1c) below or equal to 10 % based on central laboratory results * ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 1 DIABETES: * Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months * Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive) * ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 2 DIABETES: * Diagnosed with type 2 diabetes mellitus for at least 12 months * Treated with insulin for the last 3 months prior to screening. * Body Mass Index (BMI) between 22.0 and 35.0 kg/m\^2 (both inclusive)
Exclusion criteria
* A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trial product, as judged by the Investigator * A subject who has participated in any other trials involving investigational products within the 3 months preceding the start of dosing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the insulin aspart concentration curve from 0-2 hours (for subjects with type 1 diabetes) | 0-2 hours after dosing |
| Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes) | 0-24 hours after dosing |
Secondary
| Measure | Time frame |
|---|---|
| Area under the glucose infusion rate curve | 0-24 hours after dosing |
| Area under the serum insulin degludec concentration curve | 0-96 hours after dosing |
Countries
Germany
Outcome results
None listed